

INFECTION CONTROL



EDITORIAL

Infection Control—Into the Next Decade
Harvey A. Elder, MD

ORIGINAL ARTICLES

Peritonitis from Automated Peritoneal Dialysis
Bruce H. Hamory, MD; James M. Neviakias, MD; Steven K. Pearson, MSPH

Wound Infection After Simple Suture at the Emergency Ward
Michael Alkan, MD; Ziva Gefen, RN; Louis Golcman, MD

A Hospital Contingency Plan for Exotic Communicable Diseases
Beverly A. Campbell, RN, BScN; M. Dorothy Pequegnat, RN, BSc, PHN;
Alastair J. Clayton, MB, ChB, DPH, FRCP(C)

**Cost-Effectiveness of the Two-Step Skin Test for Tuberculosis
Screening of Employees in a Community Hospital**
Chinh T. Lé, MD

Nosocomial Mycobacterial Pseudoinfection in a Georgia Hospital
Richard A. Goodman, MD, MPH; J. David Smith, BS; George P. Kubica, PhD;
Ellen M. Dougherty, AB; R. Keith Sikes, DVM, MPH

**Clinical Pharmacology of Antibiotics:
The Cephalosporin Antibiotic Agents—
II. First- and Second-Generation Agents**
T. Donald Marsh, PharmD

**Infection Control and Employee Health:
Employee Work Restrictions for Infection Control**
William M. Valenti, MD

Index to Authors and Articles: 1980 to 1984

Safe for Scopes



HEPATITIS

Sporicidin, diluted 1:16, inactivates the Hepatitis B Virus in 10 minutes.

(Centers for Disease Control, Phoenix, Arizona)

Completely disinfects flexible and rigid scopes in 10 minutes with only 0.13% glutaraldehyde.

Safe to use . . . Does not cloud scope lenses nor harm metals, rubber and/or plastics. Does not stain or irritate the hands. No gloves are necessary for safety. Vapors do not irritate the eyes or nostrils.

Most effective . . . The only sterilizing solution which is fully effective against the tubercle bacillus, influenza, hepatitis and enteroviruses when diluted 1 in 16.

Stable . . . Fully effective for 30 days after activation.

Proven . . . The most effective cold sterilant and disinfectant ever registered by the E.P.A.

"Sporicidin, diluted 1 in 16, (0.13% glutaraldehyde), is effective for high level hospital disinfection . . ."

Centers for Disease Control, Atlanta, GA (Guidelines . . . revised August 1982)

"This study has determined that although E.P.A. requirements for classifying a sterilizing agent were satisfied by Cidex, they were exceeded by Sporicidin."

Journal of Dental Research, Vol. 60, March 1981 (U.S. Army Institute of Dental Research, Wash., DC)

"Sporicidin . . . was both more stable and more active against test spores than . . . Cidex and Cidex-7."

Infection Control, 1(2): 90-93, 1980



The Sporicidin Company

4000 Massachusetts Avenue, NW, Washington, DC 20016 Call Toll Free (800) 424-3733

INFECTION CONTROL

Table of Contents

Editorial

- Infection Control—Into the Next Decade** 557
Harvey A. Elder, MD

Original Articles

- Peritonitis from Automated Peritoneal Dialysis** 559
Bruce H. Hamory, MD; James M. Neviakias, MD;
Steven K. Pearson, MSPH

- Wound Infection After Simple Suture at the Emergency Ward** 562
Michael Alkan, MD; Ziva Gefen, RN; Louis Golcman, MD

- A Hospital Contingency Plan for Exotic Communicable Diseases** 565
Beverly A. Campbell, RN, BScN; M. Dorothy Pequegnat, RN, BSc, PHN;
Alastair J. Clayton, MB, ChB, DPH, FRCP(C)

- Cost-Effectiveness of the Two-Step Skin Test for Tuberculosis Screening of Employees in a Community Hospital** 570
Chinh T. Lé, MD

- Nosocomial Mycobacterial Pseudoinfection in a Georgia Hospital** 573
Richard A. Goodman, MD, MPH; J. David Smith, BS; George P. Kubica, PhD;
Ellen M. Dougherty, AB; R. Keith Sikes, DVM, MPH

- Clinical Pharmacology of Antibiotics: The Cephalosporin Antibiotic Agents—II. First- and Second-Generation Agents** 577
T. Donald Marsh, PharmD

- Infection Control and Employee Health: Employee Work Restrictions for Infection Control** 583
William M. Valenti, MD

Departments

- | | | | |
|--------------------------------|-----|-------------------------------|-----|
| Information for Authors | 552 | 1980 to 1984 Index | 586 |
| Letters to the Editor | 553 | Classified Marketplace | 592 |
| Calendar of Events | 585 | | |

The ideas and opinions expressed by contributing authors do not necessarily reflect those of the editors or publisher.

Publisher: Infection Control (ISSN-0195-9417) is published monthly by SLACK Incorporated, 6900 Grove Road, Thorofare, New Jersey 08086. Telephone: Thorofare (609) 848-1000.

Copyright 1984: All rights reserved. No part of this publication may be reproduced without written permission from the publisher.

Subscriptions: Subscription requests should be addressed to the publisher (except Japan). In Japan, contact Woodbell Scope Incorporated, 11-11, Shoto 2-chrome, Shibuya-Ku, Tokyo 150, Japan. Annual subscription price is: Individual: One year—\$35.00; Two years—\$50.00; Three years—\$65.00. Institutional: One year—\$50.00; Two years—\$65.00; Three years—\$80.00. All subscriptions, without exception, will start with the first issue published after the order is received. Back copies are available, but must be purchased separately. Cost per individual copy is \$5.00. Foreign subscribers add \$15.00 to regular rate: foreign orders, \$6.00.

Change of address: Notice should be sent to the publisher six weeks in advance of effective date. Include old and new addresses with zip codes. The publisher cannot accept responsibility for undelivered copies. Second-class postage is paid at Thorofare, New Jersey 08086. **Postmaster:** Form 3547 to SLACK Incorporated, 6900 Grove Road, Thorofare, NJ 08086.


As of Volume 1, Number 1, INFECTION CONTROL is listed in *Index Medicus*, *Current Contents—Clinical Practice*, *Hospital Literature Index*, and *Cumulative Index to Nursing and Allied Health Literature*.

10 Reasons for Warming Up to a Cold Sterilant Wavicide-01[®]

1. The *least* expensive sterilant on the market.
2. Approved as a disinfectant, using a 1:4 dilution at room temperature.
3. Ready to use, Wavicide-01 works without an activator.
4. Sporicidal, as proven by AOAC test, at 25°C (10 hrs), 40°C (5 hrs) and 60°C (1 hr).
5. Approved for use in high-power ultrasonic cleaners.
6. Proven effective in continuous 28 day use and re-use with ultrasonic systems, even in the presence of organic matter.
7. Odorless when used as a disinfectant.
8. Will not yellow hands (some disinfectants do).
9. Will not fog or corrode fiberscopes.
10. Stable, long life, *balanced glutaraldehyde* formulation.

For literature or ordering information please contact:
Wave Energy Systems, Inc.
130 East 59 Street, 14 Floor
New York, NY 10022
(212) 593-3213

➡ **Wave Energy Systems Inc.**



INFECTION CONTROL / Editorial Board

EDITOR

Richard P. Wenzel, MD
Charlottesville, Virginia

SENIOR ASSOCIATE EDITOR

William Schaffner, MD
Nashville, Tennessee

ASSOCIATE EDITORS

Sue Crow, RN, MSN
Shreveport, Louisiana

John E. McGowan, Jr., MD
Atlanta, Georgia

Dennis G. Maki, MD
Madison, Wisconsin



SLACK Incorporated
6900 Grove Road
Thorofare, New Jersey 08086

Publisher

Richard N. Roash

Managing Editor

Donna Carpenter

Consulting Editor

Eric Baloff

Assistant Editor

Linda L. Jones

Circulation Manager

Kevin J. Fenton

Advertising Manager

Melissa Warner

Advertising

Sales Representative

Wayne McCourt

Classified

Advertising Representative

Harriet E. Hampton

EDITORIAL

ADVISORY BOARD

Robert C. Aber, MD
Hershey, Pennsylvania

Charles S. Bryan, MD
Columbia, South Carolina

John P. Burke, MD
Salt Lake City, Utah

Marie B. Coyle, PhD
Seattle, Washington

Burke A. Cunha, MD
Mineola, New York

Richard E. Dixon, MD
Trenton, New Jersey

Harvey A. Elder, MD
Loma Linda, California

Bruce Farber, MD
Pittsburgh, Pennsylvania

Peter C. Fuchs, MD, PhD
Portland, Oregon

Richard A. Garibaldi, MD
Farmington, Connecticut

Donald A. Goldmann, MD
Boston, Massachusetts

Dieter H.M. Gröschel, MD
Charlottesville, Virginia

Peter A. Gross, MD
Hackensack, New Jersey

Karen Hadley, RN, MPH
New Orleans, Louisiana

David K. Henderson, MD
Bethesda, Maryland

Peter N.R. Heseltine, MD
Los Angeles, California

Cyrus C. Hopkins, MD
Boston, Massachusetts

Allen B. Kaiser, MD
Nashville, Tennessee

Harold Laufman, MD, PhD
New York, New York

William J. Ledger, MD
New York, New York

Barbara McArthur, RN, PhD
Detroit, Michigan

Rob Roy MacGregor, MD
Philadelphia, Pennsylvania

C. Glen Mayhall, MD
Richmond, Virginia

Ronald Lee Nichols, MD
New Orleans, Louisiana

Harry C. Nottebart, Jr., JD, MD
Richmond, Virginia

James E. Peacock, Jr., MD
Winston-Salem, North Carolina

Frank S. Rhame, MD
Minneapolis, Minnesota

William A. Rutala, PhD, MPH
Chapel Hill, North Carolina

William E. Scheckler, MD
Madison, Wisconsin

Robert J. Shannon, MSPH
Boston, Massachusetts

Walter E. Stamm, MD
Seattle, Washington

Charles W. Stratton, MD
Nashville, Tennessee

Timothy R. Townsend, MD
Baltimore, Maryland

William M. Valenti, MD
Rochester, New York

James Veazey, MD
Albany, New York

Kathy J. Wydra, RN
Geneva, New York

FOREIGN ADVISORY BOARD

Graham Ayliffe, MD, FRC Path.
Birmingham, England

Professor G. Berencsi
Szeged, Hungary

Professor Jaap Dankert
Groningen, Netherlands

Professor Dr. F. Daschner
Freiburg, West Germany

Lars O. Kallings, MD
Stockholm, Sweden

Professor W.B. Kędzia
Sieroca, Poland

Professor A.P. Krasilnikow
Minsk, USSR

Professor Dr. W. Marget
Munich, West Germany

Bertil Nyström, MD
Huddinge, Sweden

Ian Phillips, MA, MD, MRC Path.
London, England

Samuel Ponce de Leon, MD
Mexico City, Mexico

Hans Reber, MD
Basel, Switzerland

Professor Gerald Reybrouck
Leuven, Belgium

Manfred L. Rotter, MD, DipBact
Vienna, Austria

Theodore Sacks, MD
Jerusalem, Israel

Dr. Bernhard M. Thimm
Federal Republic of Germany

Professor Dr. med. H.P. Werner
Mainz, West Germany

Professor Dr. W. Weuffen
Greifswald, German Democratic Republic